Suppr超能文献

日本雪松和柏树花粉过敏症更新:新过敏原、交叉反应和治疗。

Japanese cedar and cypress pollinosis updated: New allergens, cross-reactivity, and treatment.

机构信息

Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.

Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Chiba, Japan.

出版信息

Allergol Int. 2021 Jul;70(3):281-290. doi: 10.1016/j.alit.2021.04.002. Epub 2021 May 4.

Abstract

Pollen from many tree species in the Cupressaceae family is a well-known cause of seasonal allergic diseases worldwide. Japanese cedar pollinosis and Japanese cypress pollinosis, which are caused by pollen from Japanese cedar (Cryptomeria japonica) and Japanese cypress (Chamaecyparis obtusa), respectively, are the most prevalent seasonal allergic diseases in Japan. Recently, the novel major Japanese cypress allergen Cha o 3 and the homologous Japanese cedar allergen Cry j cellulase were identified, and it was shown, for the first time, that cellulase in plants is allergenic. Although the allergenic components of pollen from both species exhibit high amino acid sequence identity, their pollinosis responded differently to allergen-specific immunotherapy (ASIT) using a standardized extract of Japanese cedar pollen. Pharmacotherapy and ASIT for Japanese cedar and cypress pollinosis have advanced considerably in recent years. In particular, Japanese cedar ASIT has entered a new phase, primarily in response to the generation of updated efficacy data and the development of new formulations. In this review, we focus on both Japanese cypress and cedar pollinosis, and discuss the latest findings, newly identified causative allergens, and new treatments. To manage pollinosis symptoms during spring effectively, ASIT for both Japanese cedar and Japanese cypress pollen is considered necessary.

摘要

柏科树木的花粉是引起全球季节性变应性疾病的一个重要原因。由日本扁柏(Cryptomeria japonica)花粉引起的日本扁柏花粉症和由日本花柏(Chamaecyparis obtusa)花粉引起的日本花柏花粉症是日本最常见的季节性变应性疾病。最近,新型的主要日本花柏过敏原 Cha o 3 和同源的日本扁柏过敏原 Cry j 纤维素酶被鉴定出来,这首次表明植物中的纤维素酶是具有致敏性的。尽管这两个物种花粉的致敏成分表现出高度的氨基酸序列同一性,但它们的花粉症对使用日本扁柏花粉标准化提取物的变应原特异性免疫疗法(ASIT)的反应不同。近年来,针对日本扁柏和花柏花粉症的药物治疗和 ASIT 都取得了很大进展。特别是日本扁柏 ASIT 进入了一个新阶段,主要是因为产生了更新的疗效数据和新制剂的开发。在这篇综述中,我们重点关注日本扁柏和花柏花粉症,并讨论最新的发现、新鉴定的过敏原和新的治疗方法。为了有效控制春季花粉症症状,我们认为有必要对日本扁柏和日本花柏花粉进行 ASIT。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验